#USA #Chicago #Seegene #CURECA #STAgora

Seegene Unveils CURECA™: A Revolutionary Leap in PCR Automation

Seegene Inc., a global leader in molecular diagnostics, has taken a transformative step in the field of diagnostics by unveiling its innovative system, CURECA™. This fully automated PCR testing system is making its debut at ADLM 2025 in Chicago, from July 28 to 31. This groundbreaking technology not only streamlines the diagnostic process but also sets a new standard for laboratory efficiency and accuracy.

Complete Automation of PCR Testing

CURECA™ is the world's first system to automate every aspect of the PCR testing process. From sample storage and preprocessing to nucleic acid extraction, amplification, and result analysis, the entire workflow is handled without any human intervention. This continuous operation, available 24/7, significantly reduces the risk of human errors while enhancing the reliability and consistency of test results.

One of the most remarkable features of CURECA™ is its fully automated preparation module, which tackles one of the most labor-intensive and error-prone stages in the laboratory workflow. Traditional preprocessing, especially with diverse samples such as urine, blood, sputum, and feces, often involves tedious manual tasks that can lead to inconsistencies.

The CURECA™ system successfully overcomes these challenges, even addressing the complexities associated with fecal samples, which are known to be highly viscous and contain particulates that complicate automation. By automating the preprocessing stage for all major sample types, CURECA™ alleviates long-standing obstacles in laboratory operations, leading to increased sample throughput and reduced labor demands.

Laboratory personnel can now focus on higher-value tasks, such as clinical data analysis and interpretation, allowing for more efficient resource management in high-volume testing environments. The module's versatility extends beyond PCR diagnostics, as it also supports preprocessing for other laboratory disciplines, including clinical chemistry and immunoassays, marking a significant advancement in automation across the diagnostic market.

STAgora™: A Gateway to Global Data Integration

In conjunction with CURECA™, Seegene is also presenting STAgora™, a sophisticated statistical platform designed to collect and analyze real-time data from PCR diagnostics to enhance clinical decision-making. By aggregating test data from hospitals worldwide, STAgora™ provides an integrated view of regional infection trends, hospital positivity rates, and co-infection patterns with over 40 statistical tools tailored for clinical support.

This innovative platform empowers healthcare providers to align patient test results with local and regional epidemiological data, facilitating the formulation of more accurate, data-driven treatment strategies. With STAgora™, clinicians can assess infection trends at the individual and community levels, contributing to improved diagnostic accuracy and care planning.

Fostering Global Collaboration and Partnerships

With its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ through early pilot experiences and strategic global partnerships. Earlier this year, CURECA™ garnered significant attention at the ESCMID Global 2025 congress, a leading European meeting on clinical microbiology and infectious diseases. To enhance its R&D and production capabilities in the United States, Seegene is expanding its local operations with subsidiaries, including Seegene Technologies and Seegene CURECA.

“CURECA™ and STAgora™ are not merely diagnostic tools or software; they embody a new global standard that will redefine diagnostics in clinical settings worldwide,” remarked Daniel Shin, Executive Vice President and Chief Sales and Marketing Officer at Seegene. “We will continue to leverage the technological advancements we've made over the years to drive fundamental innovation throughout the global diagnostic ecosystem.”

Tech Disclaimer: The product is currently in pre-commercialization phases. The configuration presented at ADLM 2025 is intended solely for demonstration purposes and may differ from the final commercial version in terms of functionality, specifications, and components.

About Seegene

With over 20 years of experience in research and development, manufacturing, and business management in real-time syndromic PCR technologies, Seegene has established itself as a key player in the diagnostics field. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided more than 340 million tests to over 100 countries worldwide, showcasing its capacity to test multiple pathogens simultaneously within a single tube. Explore more at Seegene.com.